SBRT: An opportunity to improve quality of life for oligometastatic prostate cancer

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Azzam, Gregory ^a   Lanciano, Rachelle ^a,b   Arrigo, Steve ^a,b   Lamond, John ^a,b   Ding, William ^b   Yang, Jun ^a,b   Hanlon, Alexandra ^c   Good, Michael ^b   Brady, Luther ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Delaware County Memorial Hospital   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgen deprivation therapy; Docetaxel; Oligometastases; Prostate cancer; SBRT

Indexed keywords

DOCETAXEL;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; MIDDLE AGED; ORGANS AT RISK; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME;

EID: 84934292042     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00101     Document Type: Article

References (18)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., editors. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute (2013). Available from: http://seer.cancer.gov/csr/1975_2011/
2. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol (1995) 13:8-10.
3. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol (2011) 8:378-82. doi: 10.1038/nrclinonc.2011.44
4. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2012) 118:2962-70. doi:10.1002/cncr.26611
5. Allan CA, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL. Androgen deprivation therapy complications. Endocr Relat Cancer (2014) 21:T119-29. doi:10.1530/ERC-13-0467
6. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer (2009) 115:2388-99. doi:10.1002/cncr.24283
7. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 31:2029-36. doi:10.1200/JCO.2012.46.5492
8. Créhange G, Roach M III, Martin E, Cormier L, Peiffert D, Cochet A, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother (2014) 18:524-34. doi:10.1016/j.canrad.2014.07.153
9. Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, et al. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naive prostate cancer. Front Oncol (2013) 3:293. doi:10.3389/fonc.2013.00293
10. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer (2013) 11:27-32. doi:10.1016/j.clgc.2012.08.003
11. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol (2014) 9:135. doi:10.1186/1748-717X-9-135
12. Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer (2014) 14:671. doi:10.1186/1471-2407-14-671
13. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 351:1513-20. doi:10.1056/NEJMoa041318
14. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 26:242-5. doi:10.1200/JCO.2007.12.4008
15. Heidenreich A, Pfister D, Merseburger A, Bartsch G. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol (2013) 64:260-5. doi:10.1016/j.eururo.2013.05.021
16. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol (2008) 18:215-22. doi:10.1016/j.semradonc.2008.04.001
17. Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol (2014) 32:707-13. doi:10.1016/j.urolonc.2014.01.004
18. Sweeney C, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol (2014) 32:5s. (Suppl; abstr LBA2).